Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.soard.2020.06.011 http://scihub22266oqcxt.onion/10.1016/j.soard.2020.06.011 32723601!7346794!32723601     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32723601.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Surg+Obes+Relat+Dis 2020 ; 16 (9): 1372-1375 Nephropedia Template TP {{tp|p=32723601|t=2020. Colorectal surgery obesity-related morbidity during COVID-19 |pdf=|usr=}}{{32723601}} gab.com Text Colorectal surgery obesity-related morbidity during COVID-19 JO: Surg Obes Relat Dis http://www.kidney.de/pget.php?&tw=1&pmid=32723601 #FOAvip Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event. Twit Text FOAVip Colorectal surgery obesity-related morbidity during COVID-19 ????Surg Obes Relat Dis http://www.kidney.de/pget.php?&tw=1&pmid=32723601 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32723601 #FOAvip English Wikipedia <ref>{{Cite pmid|32723601}}</ref> Colorectal surgery obesity-related morbidity during COVID-19 #MMPMID32723601 Montorfano L; Miret R; Rahman AU; Alonso M; Maron DJ; Roy M; Ferri F; Bejarano P; Wexner SD Surg Obes Relat Dis 2020[Sep]; 16 (9): 1372-1375 PMID32723601show ga Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus disease 2019 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event. |*Betacoronavirus[MESH] |Antibodies, Monoclonal, Humanized/*adverse effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cecal Diseases/diagnosis/*etiology/surgery[MESH] |Coronavirus Infections/complications/diagnosis/*drug therapy[MESH] |Cytokine Release Syndrome/etiology/prevention & control[MESH] |Female[MESH] |Humans[MESH] |Intestinal Perforation/diagnosis/*etiology/surgery[MESH] |Middle Aged[MESH] |Obesity, Morbid/*complications[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/diagnosis/*drug therapy[MESH]Colorectal surgery obesity-related morbidity during COVID-19 (epmc).pdf DeepDyve Pubget Overpricing